Trials / Sponsors / Albireo, an Ipsen Company
Albireo, an Ipsen Company
Industry · 5 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis | Phase 2 | 2023-01-09 |
| Enrolling By Invitation | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Biliary Atresia | Phase 3 | 2022-07-05 |
| Recruiting | Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Alagille Syndrome | Phase 3 | 2021-09-03 |
| Active Not Recruiting | Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD) Biliary Atresia | Phase 3 | 2020-07-08 |
| Completed | Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC Progressive Familial Intrahepatic Cholestasis | Phase 3 | 2018-09-28 |